Cargando…

Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) Analogs in Combination With Radiation Therapy in the CHHiP Trial

PURPOSE: CHHiP is a randomized trial evaluating moderately hypofractionated radiation therapy for treatment of localized prostate cancer. Of all participants, 97% of them had concurrent short-course hormone therapy (HT), either luteinizing hormone-releasing hormone analog (LHRHa) or 150 mg of bicalu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tree, Alison, Griffin, Clare, Syndikus, Isabel, Birtle, Alison, Choudhury, Ananya, Graham, John, Ferguson, Catherine, Khoo, Vincent, Malik, Zafar, O'Sullivan, Joe, Panades, Miguel, Parker, Chris, Rimmer, Yvonne, Scrase, Christopher, Staffurth, John, Dearnaley, David, Hall, Emma
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier, Inc 2022
Materias:	Clinical Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9119688/ https://www.ncbi.nlm.nih.gov/pubmed/35017008 http://dx.doi.org/10.1016/j.ijrobp.2021.12.160

Ejemplares similares

Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5 yr in the CHHiP trial (CRUK/06/016)
por: Staffurth, John N., et al.
Publicado: (2021)

Evaluation of erectile potency and radiation dose to the penile bulb using image guided radiotherapy in the CHHiP trial
por: Murray, Julia, et al.
Publicado: (2019)

Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
por: Wilkins, Anna, et al.
Publicado: (2015)

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
por: Dearnaley, David, et al.
Publicado: (2016)

Forward- and Inverse-Planned Intensity-Modulated Radiotherapy in the CHHiP Trial: A Comparison of Dosimetry and Normal Tissue Toxicity
por: Naismith, O.F., et al.
Publicado: (2019)

Estimates of Alpha/Beta (α/β) Ratios for Individual Late Rectal Toxicity Endpoints: An Analysis of the CHHiP Trial
por: Brand, Douglas H., et al.
Publicado: (2021)

Expression of Luteinizing Hormone-Releasing Hormone (LHRH) and Type-I LHRH Receptor in Transitional Cell Carcinoma Type of Human Bladder Cancer
por: Szabó, Zsuzsanna, et al.
Publicado: (2021)

Multi-candidate immunohistochemical markers to assess radiation response and prognosis in prostate cancer: results from the CHHiP trial of radiotherapy fractionation
por: Wilkins, Anna, et al.
Publicado: (2023)

Substantial expression of luteinizing hormone-releasing hormone (LHRH) receptor type I in human uveal melanoma
por: Treszl, Andrea, et al.
Publicado: (2013)

Luteinizing hormone-releasing hormone receptor-mediated delivery of mitoxantrone using LHRH analogs modified with PEGylated liposomes
por: He, Yingna, et al.
Publicado: (2010)

Linkage of the CHHiP randomised controlled trial with primary care data: a study investigating ways of supplementing cancer trials and improving evidence-based practice
por: Lemanska, Agnieszka, et al.
Publicado: (2020)

Synthesis of Radiolabeled Technetium- and Rhenium-Luteinizing Hormone-Releasing Hormone ((99m)Tc/Re-Acdien-LHRH) Conjugates for Targeted Detection of Breast Cancer Cells Overexpressing the LHRH Receptor
por: Calderon, Lindsay E., et al.
Publicado: (2021)

Transformation of a prostatic adenocarcinoma into squamous cell carcinoma after luteinizing hormone-releasing hormone (LHRH) agonist and radiotherapy treatment
por: Ichaoui, Hamza, et al.
Publicado: (2019)

Linking CHHiP prostate cancer RCT with GP records: A study proposal to investigate the effect of co-morbidities and medications on long-term symptoms and radiotherapy-related toxicity
por: Lemanska, Agnieszka, et al.
Publicado: (2017)

Enhanced Anti-Tumoral Activity of Methotrexate-Human Serum Albumin Conjugated Nanoparticles by Targeting with Luteinizing Hormone-Releasing Hormone (LHRH) Peptide
por: Taheri, Azade, et al.
Publicado: (2011)

Methodology for tissue sample collection within a translational sub-study of the CHHiP trial (CRUK/06/016), a large randomised phase III trial in localised prostate cancer
por: Wilkins, Anna, et al.
Publicado: (2018)

Contemporary hormone therapy with LHRH agonists for prostate cancer: avoiding osteoporosis and fracture
por: Wilson, Hannah C.P., et al.
Publicado: (2015)

Association of the genetic variants of luteinizing hormone, luteinizing hormone receptor and polycystic ovary syndrome
por: Liu, Nana, et al.
Publicado: (2012)

Characterization of Luteinizing Hormone and Luteinizing Hormone Receptor and Their Indispensable Role in the Ovulatory Process of the Medaka
por: Ogiwara, Katsueki, et al.
Publicado: (2013)

Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels
por: Popovics, Petra, et al.
Publicado: (2014)

Response of the corpus luteum to luteinizing hormone.
por: Niswender, G D
Publicado: (1981)

Hormonal treatment of pancreatic carcinoma: a phase II study of LHRH agonist goserelin plus hydrocortisone.
por: Philip, P. A., et al.
Publicado: (1993)

Luteinizing Hormone-Releasing Hormone Distribution in the Anterior Hypothalamus of the Female Rats
por: Castañeyra-Ruiz, Leandro, et al.
Publicado: (2013)

Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer
por: Ueda, Takashi, et al.
Publicado: (2021)

A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer
por: Murray, Julia, et al.
Publicado: (2020)

The utilization of basal luteinizing hormone in combination with the basal luteinizing hormone and follicle-stimulating hormone ratio as a diagnostic tool for central precocious puberty in girls
por: Chotipakornkul, Nuntika, et al.
Publicado: (2023)

Serum luteinizing hormone level and luteinizing hormone/follicle-stimulating hormone ratio but not serum anti-Müllerian hormone level is related to ovarian volume in Korean women with polycystic ovary syndrome
por: Chun, Sungwook
Publicado: (2014)

Luteinizing hormone and its dilemma in ovulation induction
por: Kumar, Pratap, et al.
Publicado: (2011)

Ganirelix and the prevention of premature luteinizing hormone surges
por: Mannaerts, Bernadette
Publicado: (2023)

Do basal Luteinizing Hormone and Luteinizing Hormone/Follicle-Stimulating Hormone Ratio Have Significance in Prognosticating the Outcome of In vitro Fertilization Cycles in Polycystic Ovary Syndrome?
por: Singh, Neeta, et al.
Publicado: (2021)

Do Basal Luteinizing Hormone and Luteinizing Hormone/ Follicle-Stimulating Hormone Ratio have Significance in Prognosticating the Outcome of In vitro Fertilization Cycles in Polycystic Ovary Syndrome?
por: Neeta, Singh, et al.
Publicado: (2021)

Do Basal Luteinizing Hormone and Luteinizing Hormone/Follicle- Stimulating Hormone Ratio have Significance in Prognosticating the Outcome of In vitro Fertilization Cycles in Polycystic Ovary Syndrome?
por: Sookaromdee, Pathum, et al.
Publicado: (2021)

Luteinizing hormone beta gene polymorphism and its effect on semen quality traits and luteinizing hormone concentrations in Murrah buffalo bulls
por: Reen, Jagish Kour, et al.
Publicado: (2018)

Future possibilities in the prevention of breast cancer: Luteinizing hormone-releasing hormone agonists
por: Spicer, Darcy V, et al.
Publicado: (2000)

The Roles of Luteinizing Hormone, Follicle-Stimulating Hormone and Testosterone in Spermatogenesis and Folliculogenesis Revisited
por: Oduwole, Olayiwola O., et al.
Publicado: (2021)

The crystal structure of the β subunit of luteinizing hormone and a model for the intact hormone
por: Larson, Steven B., et al.
Publicado: (2019)

Luteinizing Hormone Regulation of Inter-Organelle Communication and Fate of the Corpus Luteum
por: Przygrodzka, Emilia, et al.
Publicado: (2021)

Topographical localization of the receptors for luteinizing hormone- releasing hormone on the surface of dissociated pituitary cells
Publicado: (1977)

Basal luteinizing hormone and follicular stimulating hormone: is it sufficient for the diagnosis of precocious puberty in girls?
por: Lee, Dong Seong, et al.
Publicado: (2013)

Effects of growth hormone administration on luteinizing hormone secretion in healthy older men and women
por: Muniyappa, Ranganath, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_6kd6mun1rbqqf6370nirbnochg